JP2020524996A5 - - Google Patents

Download PDF

Info

Publication number
JP2020524996A5
JP2020524996A5 JP2019569226A JP2019569226A JP2020524996A5 JP 2020524996 A5 JP2020524996 A5 JP 2020524996A5 JP 2019569226 A JP2019569226 A JP 2019569226A JP 2019569226 A JP2019569226 A JP 2019569226A JP 2020524996 A5 JP2020524996 A5 JP 2020524996A5
Authority
JP
Japan
Prior art keywords
chemokine
composition
encoded
viral vector
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019569226A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020524996A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/037924 external-priority patent/WO2018232359A1/en
Publication of JP2020524996A publication Critical patent/JP2020524996A/ja
Publication of JP2020524996A5 publication Critical patent/JP2020524996A5/ja
Priority to JP2023118187A priority Critical patent/JP2023133396A/ja
Priority to JP2025048283A priority patent/JP2025089431A/ja
Pending legal-status Critical Current

Links

JP2019569226A 2017-06-16 2018-06-15 ヒトガンマデルタt細胞を介する腫瘍細胞傷害性の活性化のための方法および組成物 Pending JP2020524996A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023118187A JP2023133396A (ja) 2017-06-16 2023-07-20 ヒトガンマデルタt細胞を介する腫瘍細胞傷害性の活性化のための方法および組成物
JP2025048283A JP2025089431A (ja) 2017-06-16 2025-03-24 ヒトガンマデルタt細胞を介する腫瘍細胞傷害性の活性化のための方法および組成物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762521274P 2017-06-16 2017-06-16
US62/521,274 2017-06-16
US201862633461P 2018-02-21 2018-02-21
US62/633,461 2018-02-21
PCT/US2018/037924 WO2018232359A1 (en) 2017-06-16 2018-06-15 Methods and compositions for the activation of tumor cytotoxicity via human gamma-delta t-cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023118187A Division JP2023133396A (ja) 2017-06-16 2023-07-20 ヒトガンマデルタt細胞を介する腫瘍細胞傷害性の活性化のための方法および組成物

Publications (2)

Publication Number Publication Date
JP2020524996A JP2020524996A (ja) 2020-08-27
JP2020524996A5 true JP2020524996A5 (enExample) 2021-07-29

Family

ID=64660752

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019569226A Pending JP2020524996A (ja) 2017-06-16 2018-06-15 ヒトガンマデルタt細胞を介する腫瘍細胞傷害性の活性化のための方法および組成物
JP2023118187A Withdrawn JP2023133396A (ja) 2017-06-16 2023-07-20 ヒトガンマデルタt細胞を介する腫瘍細胞傷害性の活性化のための方法および組成物
JP2025048283A Pending JP2025089431A (ja) 2017-06-16 2025-03-24 ヒトガンマデルタt細胞を介する腫瘍細胞傷害性の活性化のための方法および組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023118187A Withdrawn JP2023133396A (ja) 2017-06-16 2023-07-20 ヒトガンマデルタt細胞を介する腫瘍細胞傷害性の活性化のための方法および組成物
JP2025048283A Pending JP2025089431A (ja) 2017-06-16 2025-03-24 ヒトガンマデルタt細胞を介する腫瘍細胞傷害性の活性化のための方法および組成物

Country Status (8)

Country Link
US (1) US20200181645A1 (enExample)
EP (1) EP3638779A4 (enExample)
JP (3) JP2020524996A (enExample)
KR (1) KR20200018586A (enExample)
CN (1) CN110770338A (enExample)
CA (1) CA3064442A1 (enExample)
IL (1) IL271274A (enExample)
WO (1) WO2018232359A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010045659A1 (en) 2008-10-17 2010-04-22 American Gene Technologies International Inc. Safe lentiviral vectors for targeted delivery of multiple therapeutic molecules
EP3319631A4 (en) 2015-07-08 2019-01-09 American Gene Technologies International Inc. HIV PREMUNICATION AND IMMUNOTHERAPY
CA3011529A1 (en) 2016-01-15 2017-07-20 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta t-cells
US10137144B2 (en) 2016-01-15 2018-11-27 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta T-cells
US10888613B2 (en) 2016-02-08 2021-01-12 American Gene Technologies International Inc. Method of producing cells resistant to HIV infection
ES2911448T3 (es) 2016-03-09 2022-05-19 American Gene Tech Int Inc Vectores combinados y métodos para el tratamiento del cáncer
EP3468617A4 (en) 2016-06-08 2020-01-22 American Gene Technologies International Inc. INTEGRATED VIRAL ADMINISTRATION SYSTEM AND RELATED METHODS
IL300730A (en) 2016-07-08 2023-04-01 American Gene Tech Int Inc Pre-HIV vaccine and immunotherapy
JP7176756B2 (ja) 2016-07-21 2022-11-22 アメリカン ジーン テクノロジーズ インターナショナル インコーポレイテッド パーキンソン病を処置するためのウイルスベクター
US11820999B2 (en) 2017-04-03 2023-11-21 American Gene Technologies International Inc. Compositions and methods for treating phenylketonuria
WO2020097049A1 (en) 2018-11-05 2020-05-14 American Gene Technologies International Inc. Vector system for expressing regulatory rna
CN114555785B (zh) * 2019-10-17 2024-12-06 香港大学 制备v-t细胞衍生的外泌体以治疗epstein-barr病毒相关癌症的方法
EP4090432A4 (en) * 2020-01-15 2024-04-17 The Regents Of The University Of California Compositions and methods for altering gamma delta t cell activity
CN115551532A (zh) * 2020-03-03 2022-12-30 美国基因技术国际有限公司 在淋巴细胞中按需表达外源性因子以治疗hiv
CN113842459B (zh) * 2021-01-18 2023-01-06 陈晓文 一种病理性血管生成抑制剂及其用途
KR20230147060A (ko) * 2021-01-21 2023-10-20 아메리칸 진 테크놀로지스 인터내셔널 인코포레이티드 조작된 nk 세포 및 암 치료 방법
JP2024507735A (ja) * 2021-02-08 2024-02-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ブチロフィリンサブファミリー3メンバーa1(btn3a1、cd277)の制御

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011133687A2 (en) * 2010-04-20 2011-10-27 President And Fellows Of Harvard College Methods and compositions for inhibition of beta2-adrenergic receptor degradation
US9745631B2 (en) * 2011-12-20 2017-08-29 Dana-Farber Cancer Institute, Inc. Methods for diagnosing and treating oncogenic kras-associated cancer
WO2014117050A2 (en) * 2013-01-26 2014-07-31 Mirimus, Inc. Modified mirna as a scaffold for shrna
CA3011529A1 (en) * 2016-01-15 2017-07-20 American Gene Technologies International Inc. Methods and compositions for the activation of gamma-delta t-cells

Similar Documents

Publication Publication Date Title
JP2020524996A5 (enExample)
JP2019501661A5 (enExample)
TWI704226B (zh) 重組溶瘤病毒組合物及其用途
JP2025089431A (ja) ヒトガンマデルタt細胞を介する腫瘍細胞傷害性の活性化のための方法および組成物
AU2017207906B2 (en) Methods and compositions for the activation of gamma-delta T-cells
Zhou et al. SIV infection of rhesus macaques of Chinese origin: a suitable model for HIV infection in humans
Reinhard et al. Vpx rescue of HIV-1 from the antiviral state in mature dendritic cells is independent of the intracellular deoxynucleotide concentration
JP2019520841A5 (enExample)
WO2010060967A2 (en) Compositions and methods for treating retrovirus infections
Huang et al. HIV-1-induced miR-146a attenuates monocyte migration by targeting CCL5 in human primary macrophages
KR20220125806A (ko) 재조합 백시니아 바이러스
Zhu et al. Immune escape of avian oncogenic Marek’s disease herpesvirus and antagonistic host immune responses
AU2020454342A1 (en) Construct and use thereof
US20150307897A1 (en) Non-viral vector
US20200056203A1 (en) Treating Animal Cancers Through Programmed Cancer Cell Death
CN114761562A (zh) 经修饰的细胞外包膜病毒
CN101654686A (zh) 一种可用于艾滋病基因治疗的多靶点siRNA重组慢病毒载体
CN115418356B (zh) 一种表达i型干扰素的hsv-1溶瘤病毒
JP7227654B2 (ja) 固形癌及び微生物感染を治療するための方法及び組成物
Monet et al. The emergence of the next-generation vaccines
JP5699093B2 (ja) パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物
US20190169636A1 (en) Directing Cancer Cells to Self-Destruct Through Vectoring Engineered Viruses
JP2006515172A (ja) パラポックスウイルス・オヴィスの組換えタンパク質およびそれ由来の医薬組成物
EP1003492A2 (en) Inhibitors of nf-kappab as activators of hsf and inducers of heat shock proteins
US20230355691A1 (en) Novel recombinant vaccinia virus and use thereof